Skip to main content
Peptides TT home

Lab guide

Peptide Purity Testing with HPLC and MS

How reversed-phase HPLC and mass spectrometry are used together to assess research peptide purity and identity, and what a 98% purity figure really means.

By Peptides TT Quality Team · Published · Updated

Two analytical techniques sit behind almost every peptide quality specification: reversed-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry (MS). One measures how much of a sample is the main component; the other confirms what that component is. Understanding how each works, and where each falls short, makes it much easier to interpret a purity figure on a certificate and to judge whether a material is suitable for a given experiment.

Why synthetic peptides contain impurities

Most research peptides are made by solid-phase peptide synthesis, in which amino acids are added one at a time to a growing chain anchored on a resin. Each coupling step is highly efficient but never perfect. Across a sequence of ten, twenty or forty residues, small inefficiencies accumulate. After cleavage from the resin, the crude product is a mixture of the target sequence and closely related by-products. Purification, almost always by preparative RP-HPLC, removes most of these, and analytical testing then measures what remains.

How reversed-phase HPLC works

HPLC separates the components of a mixture as they pass through a packed column under pressure. In the reversed-phase mode used for peptides:

  • Stationary phase. The column is packed with silica particles bonded to C18 (octadecyl) chains, creating a hydrophobic surface. Typical analytical columns are 4.6 mm wide and 150–250 mm long, with 3–5 µm particles; wide-pore (300 Å) packings are often used for larger peptides.
  • Mobile phase. Solvent A is usually water with 0.1% trifluoroacetic acid (TFA); solvent B is acetonitrile with 0.1% TFA. TFA acts as an ion-pairing agent and sharpens peaks.
  • Gradient. A small sample load is placed onto the column and the proportion of acetonitrile is increased steadily, for example from 5% to 65% B over 30 minutes. More hydrophobic species are retained longer and elute later.
  • Detection. A UV detector monitors the eluent at 214 or 220 nm, where the peptide bond absorbs strongly. A second channel at 280 nm is sometimes added for sequences containing Trp or Tyr.

Calculating area-% purity

The output is a chromatogram: absorbance plotted against retention time. Each component appears as a peak. Purity by area percentage is calculated as the area of the main peak divided by the sum of all integrated peak areas, multiplied by 100. Because nearly every peptide-like species absorbs at 214 nm, this gives a practical estimate of the relative proportion of the target sequence.

What impurities look like

Impurity typeOriginTypical appearance
Deletion sequencesA residue missed during one coupling stepSmall peaks close to the main peak
Truncated sequencesChain growth stopped early (often capped)Peaks, frequently eluting earlier
Oxidised speciesMet to sulfoxide, or Trp oxidationShoulder or small peak, usually slightly earlier
Deamidated speciesAsn or Gln converted to Asp or GluPeak very close to the main peak
Incompletely deprotected speciesSide-chain protecting group retainedLater-eluting, more hydrophobic peak
DiastereomersRacemisation of one residueVery close or co-eluting peak

Sequences containing Met or Trp, such as Bombesin and Kisspeptin-10, are monitored closely for oxidised species.

How mass spectrometry confirms identity

Mass spectrometry ionises molecules and measures their mass-to-charge ratio (m/z). Two ionisation methods dominate peptide work.

Electrospray ionisation (ESI)

ESI produces ions directly from a liquid stream and readily forms multiply charged ions, written [M+nH]n+. A peptide with a mass of 1,300 Da may appear at m/z of about 1,301 (1+), 651 (2+) and 434 (3+). Software deconvolutes these charge states back to a single neutral mass. ESI couples naturally to HPLC, giving LC-MS.

MALDI

Matrix-assisted laser desorption/ionisation mixes the sample with a light-absorbing matrix and ionises it with a laser pulse. It mostly produces singly charged [M+H]+ ions, making spectra simple to read and well suited to rapid identity checks.

Observed versus theoretical mass

The measured mass is compared with the theoretical molecular weight calculated from the sequence. Agreement within the instrument's tolerance confirms the expected molecule is present. Systematic differences are chemically informative: +16 Da suggests oxidation, +1 Da can indicate deamidation, and a loss equal to one residue mass indicates a deletion. Cyclic peptides such as Cyclo(RGDfK) have a mass 18 Da lower than their linear counterpart, which makes MS an effective check that cyclisation is complete.

Why both techniques are used together

Neither method is sufficient alone.

  • HPLC quantifies but does not identify. A single sharp peak at 99% area tells you the sample is homogeneous under those conditions, not that it is the correct sequence.
  • MS identifies but does not reliably quantify. Different species ionise with different efficiencies, so peak heights in a mass spectrum do not translate directly into proportions.

Together they answer both questions: the main component is the correct molecule, and it represents a stated share of the detected material. LC-MS goes a step further by assigning a mass to individual chromatographic peaks, which helps identify specific impurities.

Limitations to keep in mind

  • Co-elution. Two species with near-identical hydrophobicity can share one peak, inflating the apparent purity.
  • Method dependence. Purity depends on column, gradient, wavelength and integration settings. Figures from different methods are not directly comparable.
  • Invisible components. Water, TFA and other counter-ions, and inorganic salts do not absorb at 214 nm and are not counted.
  • Short sequences. Small peptides such as GRGDS can elute early, close to the solvent front, and may need adjusted conditions.

What "≥98%" means and does not mean

A specification of ≥98% by HPLC means that, under the stated method, the main peak accounts for at least 98% of the integrated UV-absorbing peak area at the detection wavelength.

It does not mean that 98% of the weighed solid is the target peptide. The lyophilized material also contains counter-ions and residual water, so net peptide content is typically lower, often 70–90%. Nor does it guarantee the absence of co-eluting or non-UV-absorbing species. Our guide on how to read a certificate of analysis explains how purity, peptide content and counter-ion figures fit together on the same document.

Summary

RP-HPLC with UV detection measures the relative proportion of the target sequence; mass spectrometry confirms its identity. Used together, they give a reliable picture of a peptide's quality, provided their limits are understood. Explore the receptor-ligand peptides and cell-adhesion peptides in our catalogue, or see how each lot is characterised on our Quality and Testing page.

RESEARCH USE ONLY

For research use only. Not for human or veterinary use. Not a drug, food, supplement or cosmetic. Not intended to diagnose, treat, cure or prevent any disease.

Peptides mentioned in this guide

  • Sealed glass vial of lyophilized Tirzepatide research peptide, 30 mg, on a navy background

    CAS 2023788-19-2

    In stock

    Tirzepatide

    Dual GIP/GLP-1 receptor agonist peptide studied in metabolic research, supplied as a 30 mg lyophilized vial for in-vitro and analytical work.

    Purity
    Per batch COA
    Vial
    30 mg

    TT$2,000.00indicative

  • Sealed glass vial of lyophilized Retatrutide research peptide, 20 mg, on a navy background

    CAS 2381089-83-2

    In stock

    Retatrutide

    Investigational GIP, GLP-1 and glucagon triple receptor agonist peptide, supplied as a 20 mg lyophilized vial for in-vitro metabolic research.

    Purity
    Per batch COA
    Vial
    20 mg

    TT$2,200.00indicative

  • Sealed glass vial of lyophilized Tesamorelin research peptide, 10 mg, on a navy background

    CAS 218949-48-5

    In stock

    Tesamorelin

    Synthetic GHRH analogue: the 44-residue human GHRH sequence with an N-terminal trans-3-hexenoyl group, supplied as a 10 mg lyophilized vial.

    Purity
    Per batch COA
    Vial
    10 mg

    TT$1,200.00indicative